Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

seekingalpha11-19

Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life.Lead candidate JANX007 demonstrates strong PSA ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484599651?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1778188472/image_1778188472.jpg","is_english":true,"pubTime":"2024-11-19 14:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2484599651","market":"hk","top_or_hot":-1,"title":"Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation","media":"seekingalpha","content":"<div>\n<p>Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life.Lead candidate JANX007 demonstrates strong PSA ...</p>\n\n<a href=\"https://seekingalpha.com/article/4738538-janux-therapeutics-stock-q3-believable-theory-strong-early-data-needs-confirmation-reiterate-hold\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 14:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4738538-janux-therapeutics-stock-q3-believable-theory-strong-early-data-needs-confirmation-reiterate-hold><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life.Lead candidate JANX007 demonstrates strong PSA ...</p>\n\n<a href=\"https://seekingalpha.com/article/4738538-janux-therapeutics-stock-q3-believable-theory-strong-early-data-needs-confirmation-reiterate-hold\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JANX","symbol_name":"Janux Therapeutics, Inc.","start_time":0,"source_url":"https://seekingalpha.com/article/4738538-janux-therapeutics-stock-q3-believable-theory-strong-early-data-needs-confirmation-reiterate-hold","article_id":"2484599651","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1778188472/image_1778188472.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484599651","pubTimestamp":1731997413,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life.Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer.JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes.Despite promising interim data, the stock's high price and early trial stage present risks; further phase 1 results will be crucial for investment decisions.   Smederevac  I covered Janux Therapeutics  in July last year. Janux develops cancer therapies using its proprietary Tumor Activated T Cell Engager  and Tumor Activated Immunomodulator  platform. These two platforms consist of five elements -  Antigen-binding domain: A","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JANX":"Janux Therapeutics, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Janux Therapeutics：可信的理论，强有力的早期数据，需要确认","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":0.9},"content_text":"Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life.Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer.JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes.Despite promising interim data, the stock's high price and early trial stage present risks; further phase 1 results will be crucial for investment decisions.   Smederevac  I covered Janux Therapeutics (NASDAQ:JANX) in July last year. Janux develops cancer therapies using its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platform. These two platforms consist of five elements -  Antigen-binding domain: A","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484599651"}